SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novavax NVAX
NVAX 7.765+3.5%2:49 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (36)6/16/2009 11:05:02 PM
From: Rock_nj   of 166
 
Head – Plant Operations
Ahmedabad, India

Novavax Inc. (Nasdaq: NVAX) has formed a joint venture with Cadila Pharmaceuticals Ltd. (Ahmedabad, India) to develop, manufacture and market vaccines, pharmaceuticals and diagnostic products in India. The joint venture will develop and commercialize Novavax’s seasonal influenza virus-like-particle (VLP)-based vaccine candidate and Cadila’s therapeutic vaccine candidates against cancer as well as its adjuvants, biogeneric and biological diagnostic products for the Indian territory. Novavax will also contribute technology to the joint venture for the development of several other VLP vaccine candidates against diseases of public health concern in that region,
such as hepatitis E and Dengue fever.

We are seeking a Head of Plant Operations to ensure availability of the products as per business plan, confirming quality norms and cost effective through efficient resource management.

novavax.com

-------------------------------------

Hmmmm.... Sounds like Novavax is setting up manufacturing in India right now. They are also apparently forming a joint company with Cadila Pharmaceuticals in India. Interesting developments. 3rd Q starts in July I believe. Perhaps more joint ventures per the CEO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext